FKA-9i

Overview

FKA-9i is an orally active anticancer agent. FKA-9i directly binds to and promotes the degradation of oncoproteins LRPPRC ( k d : 7.387 μM), YBX1 ( k d : 16.52 μM) and RPN1 ( k d : 26.82 μM). FKA-9i inhibits the MAPK signaling pathway and mitochondrial oxidative phosphorylation . FKA-9i also induces cancer cell cycle arrest, apoptosis , mitochondrial dysfunction and ROS accumulation. FKA-9i can be used in the research of tumors such as gastric cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-181098
• CAS No.: 3060515-85-4
• Molecular Formula: C30H26F2N2O9S2
• Molecular Weight: 660.66
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source